Comparison of the lymphoid toxicities of mitobronitol and busulphan in mice: Reduced B cell toxicity and improved thymic recovery as possible contributors to the reduced risk for complications following BMT with mitobronitol preconditioning

Leukemia

Volumn 11, Issue 10, 1997, Pages 1769-1774

  Szebeni, J ^a,c   Barna, K ^b   Uher, F ^a   Milosevits, J ^a   Paloczi K ^a   Gaal D ^b   Petranyi G G ^a   Kelemen, E ^a  

^a National Institute of Haematology and Immunology Budapest   (Hungary)

^b NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Bone marrow transplantation; Busulphan; Chronic granulocytic leukemia; Dibromomannitol; Myelosuppression

Indexed keywords

BUSULFAN; MITOBRONITOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; LYMPHATIC SYSTEM; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; THYMUS;

EID: 0030665240     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2400741     Document Type: Article

References (12)

1. Vaughan WP, Dennison JD, Reed EC, Klassen L, McGuire TR, Sanger WG, Kumar PP, Warkentin PI, Gordon BG, Bierman PJ, Coccia PF, Armitage JO. Improved results of allogeneic bone marrow transplantation for advanced hematological malignancy using busulfan, cyclophosphamide and etoposide as cytoreductive and immunosuppressive therapy. Bone Marrow Transplant 1991; 8: 489-495.
2. Wiebe VJ, Smith BR, DeGregorio MW, Rappaport JM. Pharmacology of agents used in bone marrow transplant conditioning regimens. Crit Rev Oncol Hematol 1992; 13: 241-270.
3. Kelemen E, Jakab K, Váradi G, Jánossa M, Földi J, Dénes R. Non-supralethal mitobronitol/cytarabine/cyclophosphamide conditioning without irradiation before bone marrow transplantation for accelerated chronic granulocytic leukemia. Leukemia 1993; 7: 939-945.
4. Bandini G, Belardinelli A, Rosti G, Calori E. Toxicity of high-dose busulphan and cyclophosphamide as conditioning therapy for allogeneic bone marrow transplantation in adults with haematological malignancies. Bone Marrow Transplant 1994; 13: 577-581.
5. Ringdén O, Ruutu T, Remberger M, Nikoskelainen J, Volin L, Vindelov L, Parkkali T, Lenhoff S, Sallerfors B, Ljungman P, Mellander L, Jacobsen N. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood 1994; 83: 2723-2730.
6. Xun CQ, Thompson JS, Jennings CD, Brown SA, Widmer MB. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood 1994; 83: 2360-2367.
7. Vey N, De Prijck B, Faucher C, Stoppa AM, Sainty D, Lafage M, Bouabdallah R, Chabannon C, Camerlo J, Gastaut JA, Maraninchi D, Blaise D. A pilot study of busulfan and melphalan as preparatory regimen prior to allogeneic bone marrow transplantation in refractory or relapsed hematological malignancies. Bone Marrow Transplant 1996; 18: 495-499.
8. 2) in patients with hematological malignancies. Bone Marrow Transplant 1996; 17: 329-333.
9. Storek J. Reconstitution of T and B cells following marrow transplantation. Clin Immunol Newslett 1995; 15: 133-136.
10. Storek J, Witherspoon RP, Storb R. T cell reconstitution after bone marrow transplantation into adult patients does not resemble T cell development in early life. Bone Marrow Transplant 1995; 16: 413-425.
11. Storek J, Witherspoon RP, Webb D, Storb R. Lack of B cell precursors in marrow transplant recipients with chronic graft-versus-host disease. Am J Hematol 1996; 52: 82-89.
12. Ferrara JLM, Cooke KR, Pan L, Krenger W. The immunopathophysiology of acute graft-versus-host-disease. Stem Cells 1996; 14: 473-489.